Skip to content
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Financials & AGM Materials

2026

Q1

Quarterly Press Release

10-Q

Q2

Quarterly Press Release

10-Q

Q3

Q4

AGM Materials

2025

Q1

Quarterly Press Release

10-Q

Q2

Quarterly Press Release

10-Q

Q3

Quarterly Press Release

10-Q

Q4

Quarterly Press Release

10-K

AGM Materials

Form of Proxy

Notice and Access Notification – Internet Availability

Notice of Meeting and Information Circular

Notice of Meeting

2024

Q1

Quarterly Press Release

10-Q

Q2

Quarterly Press Release

10-Q

Q3

Quarterly Press Release

10-Q

Q4

Quarterly Press Release

Financial Statements

MD&A

10-K

AGM Materials

Form of Proxy

Notice and Access Notification – Internet Availability

Notice of Meeting and Information Circular

Notice of Meeting

2023

Q1

Quarterly Press Release

10-Q

Q2

Quarterly Press Release

Financial Statements

MD&A

Q3

Quarterly Press Release

Financial Statements

MD&A

Q4

Quarterly Press Release

Financial Statements

MD&A

10-K

AGM Materials

Form of Proxy

Notice and Access Notification – Internet Availability

Notice of Meeting and Information Circular

Notice of Meeting

2022

Q1

Quarterly Press Release

10-Q

Q2

Quarterly Press Release

10-Q

Q3

Quarterly Press Release

10-Q

Q4

Quarterly Press Release

10-K

AGM Materials

Form of Proxy – for Registered Shareholders

Notice and Access Notification – Internet Availability

Notice of Meeting and Information Circular

Notice of Meeting

2021

Q1

10-Q

10-Q

Q2

Quarterly Press Release

10-Q

Q3

Quarterly Press Release

10-Q

Q4

Quarterly Press Release

10-Q

AGM Materials

2021 Annual Report

Form of Proxy – for Registered Shareholders

Notice and Access Notification – Internet Availability

Notice of Meeting and Information Circular

Notice of Meeting

Voting Instruction Form – for non-Registered Shareholders

Special Meeting Materials June 13, 2025

  • InMed – Notice of Meeting and Information
  • Notice of Meeting and Record Date
  • Reminder letter – Special Meeting of Shareholders
  • InMed – Special Meeting – Form of Proxy_Final
  • Notice of Meeting and Record Date Amended

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • Articles and Videos
  • Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step
  • The Evolving Alzheimer’s Disease Landscape

© Copyright 2026 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*